Michael Heider
0000-0001-6218-8828
Publication & Citation Trends
Publications
0 total
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response OA
Cited by 1
Semantic Scholar
P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA OA
Cited by 0
Semantic Scholar
Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma OA
Cited by 7
Semantic Scholar
The OTUD6B‐LIN28B‐MYC axis determines the proliferative state in multiple myeloma OA
Cited by 18
Semantic Scholar
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma OA
Cited by 25
Semantic Scholar
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution OA
Cited by 56
Semantic Scholar
Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.
Cited by 4
Semantic Scholar
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma OA
Cited by 9
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(11)
Gear and Bearing Dynamics Analysis
(11)
Tribology and Lubrication Engineering
(9)
Protein Degradation and Inhibitors
(9)
Ubiquitin and proteasome pathways
(6)
Affiliations
Munich University of Applied Sciences
University of Augsburg
German Cancer Research Center
TUM Klinikum
KUKA (Germany)